Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D Drug Discount Data Is Not Commercial Tool, CMS' Blum Says

Executive Summary

The Centers for Medicaid and Medicare Services is wary about drug industry requests for detailed, claims-level information to support invoices on the drug discounts given to Medicare Part D beneficiaries who have reached the coverage gap

You may also be interested in...



Annual Biopharma Fee Estimates Need More Transparency, BIO Says

The biopharmaceutical industry is pushing for greater transparency around the data used by the federal government to generate preliminary estimates of the market-based fees owed to the government by individual manufacturers and importers in 2011.

Annual Biopharma Fee Estimates Need More Transparency, BIO Says

The biopharmaceutical industry is pushing for greater transparency around the data used by the federal government to generate preliminary estimates of the market-based fees owed to the government by individual manufacturers and importers in 2011.

Orphan Drug “Improvements” May Be Undercut By New Market Share Fees

The Treasury Department’s plans for implementing the branded drug market share fee program mandated by the Affordable Care Act have raised concerns that investment in orphan drug development could be discouraged by a “narrow” reading of the law.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052300

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel